GENFIT Assembles Four International Experts for it's Scientific Advisory Board
News Oct 30, 2008
In the field of cardiometabolic diseases and diabetes, the experts are:
Pr Nikolaus Marx, Professor of Medicine and Cardiology at the University of Ulm (Germany), specializes in cardiovascular disease. He received the G.B Morgagni award in 2004.
Pr Markus Stoffel, Professor of Molecular Biology at the EHT in Zurich (Switzerland), specializes in biological and genetic mechanisms that regulate the homeostasis of glucose and lipids.
Pr Arnold von Eckardstein, Professor of Medicine and President of the Institute of Clinical Chemistry of the Zurich University Hospital, is an expert in metabolism of HDL and atherosclerosis.
Pr Gerald F. Watts, Professor of Medicine and Pharmacology at the University of Western Australia (Crawley), specializes in lipid disorders and the metabolic syndrome.
“It’s a great privilege for us to have assembled such a distinguished group of leading experts in our Scientific Advisory Board. Our activities in metabolic and cardiovascular fields and especially our programs in diabetes will greatly benefit from their expertise” stated Professor Bart Staels, President of the Scientific Advisory Board and cofounder of GENFIT. Jean-François Mouney, Chairman and Chief Executive Officer and cofounder of GENFIT, added “We are honored to have these renowned international experts joining our Scientific Advisory Board. Their decision to join our team is recognition of our therapeutic development strategy on an international level and reinforces our scientific approaches to prevent and fight today’s major diseases. Our Scientific Advisory Board will be extended in the coming weeks with experts in neurodegenerative diseases.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018